Table: Outcomes in active arm patients, comparing those with pre-operative (post-intervention) phosphate < 0.8 mmol/L vs those with 0.8+ mmol/L.

| **Outcome** | **Observations** | **Total\*** | **< 0.8 mmol/L** | **0.8+ mmol/L** | **Effects** |
| --- | --- | --- | --- | --- | --- |
| LOS ITU (days) | 193 | 2 [0, 3] | 1 [0, 4] | 2 [0, 3] | RR 0.94 (0.57 to 1.53); p = 0.8 |
| Any ITU stay | 193 |  |  |  | OR 0.72 (0.36 to 1.42); p = 0.34 |
| *No* |  | 58 (30.1%) | 18 (35.3%) | 40 (28.2%) |  |
| *Yes* |  | 135 (69.9%) | 33 (64.7%) | 102 (71.8%) |  |
| LOS hospital (days) | 194 | 9.5 [7, 14] | 10 [7, 14] | 9 [7, 14] | RR 1.04 (0.8 to 1.34); p = 0.76 |
| Grade 3+ complications | 193 |  |  |  | OR 1.63 (0.61 to 4.34); p = 0.33 |
| *None/<Grade III* |  | 173 (89.6%) | 43 (86%) | 130 (90.9%) |  |
| *Grade III+* |  | 20 (10.4%) | 7 (14%) | 13 (9.1%) |  |
| Any readmission by 8 weeks | 191 |  |  |  | OR 0.66 (0.29 to 1.5); p = 0.32 |
| *No* |  | 146 (76.4%) | 40 (81.6%) | 106 (74.6%) |  |
| *Yes* |  | 45 (23.6%) | 9 (18.4%) | 36 (25.4%) |  |
| Any readmission by 6 months | 186 |  |  |  | OR 0.68 (0.34 to 1.38); p = 0.29 |
| *No* |  | 113 (60.8%) | 31 (67.4%) | 82 (58.6%) |  |
| *Yes* |  | 73 (39.2%) | 15 (32.6%) | 58 (41.4%) |  |
| Any adverse events | 194 |  |  |  | 2.341 (1.19 to 4.59); p = 0.01 |
| *No* |  | 137 (70.6%) | 29 (56.9%) | 108 (75.5%) |  |
| *Yes* |  | 57 (29.4%) | 22 (43.1%) | 35 (24.5%) |  |
| Any serious adverse events | 194 |  |  |  | 0.851 (0.26 to 2.74); p = 0.79 |
| *No* |  | 177 (91.2%) | 47 (92.2%) | 130 (90.9%) |  |
| *Yes* |  | 17 (8.8%) | 4 (7.8%) | 13 (9.1%) |  |
|  |  |  |  |  |  |

\*Values are Medians[IQR] or n(%).

Rate Ratios (RR) were estimated using unadjusted quasi-Poisson regression. Odds-ratios (OR) were estimated using unadjusted logistic regression. Variables are coded such that RRs or ORs > 1 reflect worse outcomes in the group where pre-operative phosphate was < 0.8 mmol/L vs those with 0.8+ mmol/L.